EPS for Applied Genetic Technologies Corporation (AGTC) Expected At $-0.25 as of May, 9

April 17, 2018 - By Jenna Rose

Applied Genetic Technologies Corporation (NASDAQ:AGTC) Corporate Logo
During 2017 Q4 the big money sentiment decreased to 0.55. That’s change of 0.02, from 2017Q3’s 0.57. 10 investors sold all, 21 reduced holdings as Applied Genetic Technologies Corporation ratio dived. 7 grew positions while 10 funds acquired positions. Funds hold 6.64 million shares thus 2.25% less from 2017Q3’s 6.79 million shares.
Illinois-based Citadel Advsr Lc has invested 0% in Applied Genetic Technologies Corporation (NASDAQ:AGTC). Geode Management Limited Co invested in 0% or 108,951 shs. Susquehanna International Grp Inc Llp owns 13,496 shs. 107,700 are held by Spark Invest Mngmt Limited Liability. Deutsche Bancorp Ag owns 54,023 shs. Morgan Stanley owns 0% invested in Applied Genetic Technologies Corporation (NASDAQ:AGTC) for 58,122 shs. Fmr Ltd Liability Corp holds 0% or 290,530 shs in its capital. Panagora Asset Management reported 0% in Applied Genetic Technologies Corporation (NASDAQ:AGTC). Two Sigma Secs Limited Company has invested 0% of its capital in Applied Genetic Technologies Corporation (NASDAQ:AGTC). Ameriprise Financial has 12,000 shs. Dimensional Fund Lp owns 508,118 shs. Renaissance Techs Ltd Llc reported 0% in Applied Genetic Technologies Corporation (NASDAQ:AGTC). Bnp Paribas Arbitrage Sa has 0% invested in Applied Genetic Technologies Corporation (NASDAQ:AGTC). Price T Rowe Associate Md, Maryland-based fund reported 189,981 shs. Mufg Americas Corporation invested in 0% or 225 shs.

Applied Genetic Technologies Corporation (NASDAQ:AGTC)’s earnings release is awaited by WallStreet on May, 9, according to RTT. Analysts forecast 400.00 % diference or $-0.25 from the $-0.05 EPS from 2017. -13.79 % EPS growth is what analysts predict. $-0.29 EPS was published for last [previous quarter]. Its shares touched $4.9 on during the last trading session after 2.97% change.Applied Genetic Technologies Corporation has volume of 102,927 shares. Since April 17, 2017 AGTC has declined 39.42% and is downtrending. The stock underperformed the S&P 500 by 50.97%.

Applied Genetic Technologies Corporation, a clinical-stage biotechnology company, develops transformational genetic therapies for patients suffering from rare and debilitating diseases.The company has $88.71 million market cap. The company's lead products consist of four ophthalmology development programs across three targets, including X-linked retinoschisis that is in Phase I/II clinical trials; X-linked retinitis pigmentosa, which is in Phase I/II clinical trials; and achromatopsia that is in Phase I/II clinical trials for the treatment of inherited retinal diseases, as well as a preclinical program in adrenoleukodystrophy, which is a disease of the central nervous system and otology.Last it reported negative earnings. It has collaboration agreements with Biogen MA, Inc., 4D Molecular Therapeutics, Synpromics Limited, and Bionic Sight, LLC, as well as the University of Florida Research Foundation.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.